賴 峻毅

Medicine & Life Sciences

1. Hamman-Rich Syndrome 100%
2. Breast Neoplasms 99%
3. Ubiquitin-Conjugating Enzymes 90%
4. Oxaliplatin 82%
5. Running 79%
6. Erlotinib Hydrochloride 79%
7. Histone Deacetylase Inhibitors 73%
8. Mutation 70%
9. Down-Regulation 65%
10. Biomarkers 63%
11. Elderly 63%
12. Non-Small Cell Lung Carcinoma 62%
13. Neoplasms 60%
14. Induced Pluripotent Stem Cells 58%
15. Anemia 56%
16. Therapeutics 54%
17. Genes 54%
18. Obturator Hernia 53%
19. heterochromatin-specific nonhistone chromosomal protein HP-1 50%
20. ErbB Receptors 49%
21. Colorectal Neoplasms 49%
22. frataxin 48%
23. Heterotaxy Syndrome 47%
24. Psoas Abscess 47%
25. Hemolysis 46%
26. palbociclib 46%
27. Microsatellite Instability 46%
28. DNA-Activated Protein Kinase 45%
29. Dioxygenases 45%
30. Psoas Muscles 44%
31. Drug Therapy 44%
32. C-Reactive Protein 43%
33. Friedreich Ataxia 43%
34. Medical Oncology 43%
35. Xeroderma Pigmentosum 41%
36. Appendix 41%
37. Spinal Muscular Atrophy 40%
38. Taxoids 40%
39. Recombinational DNA Repair 40%
40. Aspiration Pneumonia 40%
41. Neuroendocrine Carcinoma 40%
42. Cetuximab 39%
43. Population 38%
44. Paclitaxel 37%
45. Pancreatic Neoplasms 36%
46. Respiratory Insufficiency 36%
47. Elastic Modulus 36%
48. Protein-Tyrosine Kinases 35%
49. Neuroendocrine Tumors 35%
50. Appendicitis 35%